Patents by Inventor Richard William Frith

Richard William Frith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenyl-triazole compounds for PDE-IV inhibition
    Patent number: 6248769
    Abstract: Novel compounds which are effective PDE IV inhibitors are disclosed. These compounds have the general structure of: where R1, R2, R3, R4, X1, X2 and Z are described herein. The compounds possess improved PDE IV inhibition as compared to rolipram as well as with improved selectivity with regard to PDE III inhibition. Pharmaceutical compositions containing the same and methods of treatment are also disclosed.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: June 19, 2001
    Assignee: Euro-Celtique S.A.
    Inventors: David John Cavalla, Mark Chasin, Lloyd J. Dolby, Richard William Frith
  • Aryl imidazole compounds having phosphodiesterase IV inhibitory activity
    Patent number: 6103749
    Abstract: Novel compounds which are effective PDE IV inhibitors are disclosed. These compounds have the general structure of: ##STR1## where R.sub.1, R.sub.2, R.sub.3, R.sub.4, X.sub.1, X.sub.2 and Z are described herein. The compounds possess improved PDE IV inhibition as compared to rolipram as well as with improved selectivity with regard to PDE III inhibition. Pharmaceutical compositions containing the same and methods of treatment are also disclosed.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: August 15, 2000
    Assignee: Euro-Celtique S.A.
    Inventors: David John Cavalla, Mark Chasin, Lloyd J. Dolby, Richard William Frith
  • Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
    Patent number: 5922751
    Abstract: Novel compounds which are effective PDE IV inhibitors are disclosed The compounds possess similar or improved PDE IV inhibition as compared to rolipram, with improved selectivity with regard to, e.g., PDE III inhibition. Preferred compounds are 3-(3-cyclopentyloxy-4-methoxy-benzylamino)-4-hydroxymethyl pyrazole and 3-(3-cyclopentyloxy-4-methoxybenzylamino)-4-methoxymethylpyrazole.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: July 13, 1999
    Assignee: Euro-Celtique, S.A.
    Inventors: David John Cavalla, Mark Chasin, Lloyd J. Dolby, Richard William Frith